Estamos no ar no ! Saiba mais

Viridian Therapeutics

VRDN

Valor de mercado US$ 2,16 bi

19,03 USD

-0,53

2,71%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

19,05

+0,02

0,11%

1 dia

-2,71%

5 dias

0,16%

1 mês

-15,2%

3 meses

5,55%

6 meses

29,81%

No acumulado do ano

-37,97%

1 ano

-17,3%

5 anos

14,5%

10 anos

-82,38%

Sobre: Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Funcionários: 252

Saúde Biotecnologia

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 33,3%

Neutro 66,7%

Negativo 0%

Viridian Therapeutics: Two Products, One Commercial Buildout

Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.

Viridian Therapeutics: Two Products, One Commercial Buildout

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 12:45pm ET. A live webcast of the fireside chat can be accessed under “Events and Presentations” on the Invest.

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter for Viridian as a commercial-stage company,” said Steve.

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Zacks Investment Research

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval

Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.

Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye Disease Transcript

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.'s (NASDAQ:VRDN) new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze).

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the.

Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Viridian Therapeutics is positioned to transition from late-stage biotech to commercial rare disease player with its TED franchise. Veligrotug's pivotal Phase 3 data in active and chronic TED and an FDA PDUFA date of June 30, 2026, create a near-term commercial entry point. Elegrobart, a subcutaneous follow-on asset, targets market expansion by reducing treatment barriers and is planned for a Q1 2027 BLA submission.

Viridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market Appreciates

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™